IRIS
ASCIERTO, PAOLO ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.578
NA - Nord America 4.506
EU - Europa 2.061
SA - Sud America 331
AF - Africa 153
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.646
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.283
SG - Singapore 3.896
CN - Cina 1.105
VN - Vietnam 943
JP - Giappone 631
FR - Francia 594
IT - Italia 462
RU - Federazione Russa 382
HK - Hong Kong 303
BR - Brasile 225
DE - Germania 165
IN - India 162
BD - Bangladesh 114
CA - Canada 98
NL - Olanda 89
IQ - Iraq 88
GB - Regno Unito 84
MX - Messico 75
UA - Ucraina 59
PH - Filippine 47
FI - Finlandia 38
TH - Thailandia 36
AR - Argentina 32
ZA - Sudafrica 32
KR - Corea 30
ES - Italia 29
PK - Pakistan 24
EG - Egitto 23
ID - Indonesia 20
PL - Polonia 19
EC - Ecuador 17
TR - Turchia 17
IE - Irlanda 16
JO - Giordania 16
MY - Malesia 16
VE - Venezuela 16
CH - Svizzera 14
KE - Kenya 14
SE - Svezia 14
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PY - Paraguay 11
TW - Taiwan 11
AZ - Azerbaigian 10
CI - Costa d'Avorio 10
SA - Arabia Saudita 10
TN - Tunisia 10
DZ - Algeria 9
IL - Israele 9
JM - Giamaica 9
BG - Bulgaria 8
CO - Colombia 8
MA - Marocco 8
AL - Albania 7
BO - Bolivia 7
CL - Cile 7
LB - Libano 7
AT - Austria 6
AU - Australia 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
EE - Estonia 6
LT - Lituania 6
NG - Nigeria 6
PT - Portogallo 6
RS - Serbia 6
AM - Armenia 5
BE - Belgio 5
BY - Bielorussia 5
CZ - Repubblica Ceca 5
PA - Panama 5
PS - Palestinian Territory 5
CY - Cipro 4
GT - Guatemala 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LV - Lettonia 4
PE - Perù 4
RO - Romania 4
SY - Repubblica araba siriana 4
AD - Andorra 3
BH - Bahrain 3
ET - Etiopia 3
GA - Gabon 3
GR - Grecia 3
HN - Honduras 3
IR - Iran 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TG - Togo 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
CG - Congo 2
CM - Camerun 2
Totale 14.571
Salva come PNG Salva come JPEG
Città #
San Jose 2.182
Singapore 1.482
Tokyo 616
Lauterbourg 523
Ashburn 439
Hong Kong 275
Ho Chi Minh City 267
Hanoi 211
Beijing 160
New York 147
Los Angeles 99
Naples 99
Moscow 90
Santa Clara 90
Council Bluffs 79
Hefei 74
Amsterdam 68
Dallas 53
Chandler 47
Mexico City 45
Da Nang 40
Frisco 40
Frankfurt am Main 39
Haiphong 38
Orem 38
Rome 38
Baghdad 37
Buffalo 36
Memphis 34
São Paulo 33
Toronto 33
Chicago 32
Montreal 32
Munich 32
Milan 25
The Dalles 24
Jacksonville 22
Boston 20
Brooklyn 19
Shanghai 19
Bangkok 18
Denver 18
Millbury 17
Phoenix 17
Johannesburg 16
Napoli 16
Mumbai 15
Amman 14
Cairo 14
Houston 14
Hải Dương 14
Nairobi 14
Redondo Beach 14
Seattle 14
Seoul 14
Warsaw 14
Biên Hòa 13
London 13
Nanjing 13
Atlanta 12
Boardman 12
Des Moines 12
Princeton 12
Turku 12
Contursi Terme 11
Lahore 11
San Francisco 11
Stockholm 11
Tashkent 11
Wilmington 11
Woodbridge 11
Ann Arbor 10
Casandrino 10
Chennai 10
Nuremberg 10
Guangzhou 9
Kuala Lumpur 9
Poplar 9
Quảng Ngãi 9
Can Tho 8
Charlotte 8
Helsinki 8
Miami 8
New Delhi 8
Newark 8
Quận Ba 8
Thái Bình 8
Baku 7
Bari 7
Cape Town 7
Hưng Yên 7
Manchester 7
Pune 7
Ankara 6
Asunción 6
Bắc Giang 6
Chengdu 6
Erbil 6
Falkenstein 6
Genoa 6
Totale 8.320
Salva come PNG Salva come JPEG
Nome #
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up 260
Integrated genomics identifies MiR-181/TFAM pathway as a critical driver of drug resistance in melanoma 213
Innate Immune Cells in Melanoma: Implications for Immunotherapy 186
FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy 178
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 169
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): A population-based study 163
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 149
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 142
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 137
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents 134
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab 132
Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma 120
Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes’ iTNF-α expression 114
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies 114
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? 112
Nemo binding domain peptide could induce apoptosis in several melanoma cell lines 110
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells 109
Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients 109
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 106
Severe protracted intestinal cryptosporidiosis associated with interferon g deficiency: pediatric case report. 106
NEMO-binding domain peptide induces apoptosis of human melanoma cells through inhibition of constitutive NF-kB activation 103
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps 99
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 92
HHV-8 prevalence, immunosuppression and Kaposi’s sarcoma in South Italy 87
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial 78
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 70
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. 68
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma 64
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 60
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: A retropective study 57
Expression of the anti-apoptotic protein BAG3 in human melanomas. 55
Where Reflectance Confocal Microscopy Provides the Greatest Benefit for Diagnosing Skin Cancers: The Experience of the National Cancer Institute of Naples 53
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma 53
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma 49
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial 49
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma 47
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 46
Prognostic value of serum VEGF in melanoma patients: a pilot study 44
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 43
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab 43
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 43
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301 43
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma 42
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 42
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 41
When rarity meets thoracic cancers: a narrative review from ITMIG 2024 41
The role of BRAF V600 mutation in melanoma 41
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 40
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 39
Defining the critical hurdles in cancer immunotherapy 39
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial 39
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study 38
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma 38
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma 38
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma 37
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 37
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy 37
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 37
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 37
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 37
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial 36
Emerging therapeutics for melanoma 36
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) 35
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis 35
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations 35
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery 34
Clinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational Study 34
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy 34
Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma 34
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts 34
Melanoma pathophysiology and drug targets 34
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma 34
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort 34
Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 34
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP) 33
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy 33
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors 33
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients 33
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for 33
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 32
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial 32
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018) 32
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma 32
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma 32
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors 32
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, 10.1038/s41591-023-02583-2) 32
Antitumor Activity of BRAF Inhibitor and IFN alpha Combination in BRAF-Mutant Melanoma 31
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 31
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma 31
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies 31
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 31
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma 31
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma 31
Combination therapy: the next opportunity and challenge of medicine 30
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations 30
Use of artificial intelligence chatbots in clinical management of immune-related adverse events 30
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients 30
CD73 as biomarker of advanced melanoma response to immunotherapy 30
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations 30
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters 29
Totale 6.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.734
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.734
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 0 4
2021/2022222 0 4 0 1 1 3 4 15 131 9 16 38
2022/2023134 17 5 3 6 19 10 0 13 16 20 9 16
2023/2024149 10 20 24 17 6 11 2 17 2 2 23 15
2024/2025949 47 41 11 17 38 62 95 57 84 97 316 84
2025/202613.700 187 166 240 719 2.952 1.236 1.814 2.335 2.390 954 517 190
Totale 15.354